Efficacy analysis of DPMAS+PE in the treatment of acute-on-chronic liver failure
DPMAS+PE治疗慢加急性肝衰竭的疗效分析

摘要

目的 探究双重血浆分子吸附系统（DPMAS）+血浆置换（PE）治疗慢加急性肝衰竭的效果。方法 选择2020年3月-2022年3月在本院接受治疗的患者52例为研究对象，并随机分组。对照组通过血浆置换治疗，试验组在前者基础上采取双重血浆分子吸附系统治疗。对比2组患者的治疗有效率、肝功能与凝血指标，也比较不良反应发生率。结果 试验组的治疗有效率高，不良反应发生率低，在肝功能指标与凝血指标对比中，均存在显著差异。结论 对于慢加急性肝衰竭患者的治疗，采取双重血浆分子吸附系统与血浆置换的联合应用，疗效显著，也具有良好的安全性，值得推广。

Abstract

Objective To explore the effect of dual plasma molecular adsorption system (DPMAS) + plasma exchange (PE) in the treatment of acute-on-chronic liver failure.
Methods A total of 52 patients who were treated in our hospital from March 2020 to March 2022 were selected as the research subjects and randomly divided into groups. The control group was treated with plasma exchange, and the experimental group was treated with dual plasma molecular adsorption system on the basis of the former. The treatment efficiency, liver function and coagulation indexes of the two groups were compared, and the incidence of adverse reactions was also compared.
Results The treatment efficiency of the experimental group was high, and the incidence of adverse reactions was low. There were significant differences in liver function indexes and coagulation indexes.
Conclusion   For the treat- ment of patients with acute-on-chronic liver failure, the combined application of dual plasma molecular adsorption system and plasma exchange has significant curative effect and good safety, which is worthy of promotion.